Developed by Abbott, Proclaim DRG therapy claims to be the “first and only” DRG technology that gained approval for treating CRPS of the lower limbs. Credit: Sundry Photography / Shutterstock.

由Abbott开发的Proclaim DRG疗法声称是“首个且唯一”获得批准用于治疗下肢CRPS的DRG技术。图片来源：Sundry Photography / Shutterstock。

Abbott has launched a “next-generation” delivery system to streamline the electrode implantation process for its Proclaim DRG neurostimulation system.

Abbott推出了一种“下一代”输送系统，以简化其Proclaim DRG神经刺激系统的电极植入过程。

This advancement aims to improve treatments for individuals with complex regional pain syndrome (CRPS) types 1 and 2, which are known for causing extreme pain.

这一进展旨在改善复杂区域疼痛综合征（CRPS）1型和2型患者的治疗，这两种类型以引发剧烈疼痛而著称。

According to the company, the dorsal root ganglion (DRG) is a nerve cell cluster present along the spine that regulates pain signals from certain regions such as the hip, ankle and foot.

据该公司称，背根神经节（DRG）是脊柱沿线存在的神经细胞簇，负责调节来自髋部、踝关节和足部等特定区域的疼痛信号。

Developed by the company, the Proclaim DRG therapy claims to be the “first and only” DRG technology that gained approval for treating CRPS of the lower limbs.

该公司开发的Proclaim DRG疗法声称是“首个也是唯一”获得批准用于治疗下肢CRPS的DRG技术。

This system comprises an implantable pulse generator (tiny battery) that generates electrical stimulation.

该系统包括一个可植入的脉冲发生器（微型电池），能够产生电刺激。

It also features leads to assist in delivering stimulation to the DRG. Post-implantation, targeted stimulation alleviates the symptoms by “disrupting” pain signals.

它还具有引导线，有助于将刺激传递到DRG。植入后，针对性的刺激通过“干扰”疼痛信号来缓解症状。

Notably, four out of five users of the Proclaim DRG system have experienced pain relief, reducing pain intensity by an average of 81%, stated the company.

该公司表示，值得注意的是，五分之四的 Proclaim DRG 系统用户经历了疼痛缓解，平均减少了 81% 的疼痛强度。

The delivery system is said to be crucial for the precise placement of electrodes within the DRG’s anatomy.

据说，该输送系统对于将电极精确放置在DRG解剖结构内至关重要。

Its improved manoeuvrability and durability aim to simplify the implant procedure for physicians.

其改进的可操作性和耐用性旨在简化医生的植入程序。

Abbott noted that DRG placement involves using a needle to access the epidural space and guiding the lead to the DRG under image guidance.

Abbott指出，DRG放置涉及使用针头进入硬膜外空间，并在影像引导下将导线引导至DRG。

Abbott neuromodulation medical director Allen Burton said: “Research shows treating CRPS with targeted DRG neurostimulation results in significantly better outcomes in terms of pain relief and functional improvements than traditional spinal cord stimulation approaches.

雅培神经调节医疗总监艾伦·伯顿表示：“研究表明，与传统的脊髓刺激方法相比，使用靶向DRG神经刺激治疗CRPS在缓解疼痛和功能改善方面能带来明显更好的效果。

“Abbott is continually working to improve DRG technology to better assist physicians in improving patient outcomes. The easier the procedure, the more patients will benefit from it, helping them to live more active, fuller lives with their chronic pain under control.”

“Abbott一直在努力改进DRG技术，以更好地协助医生改善患者的治疗效果。手术越简单，受益的患者就越多，这将帮助他们控制慢性疼痛，过上更积极、更充实的生活。”